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cardiovascular and renal complications are the predominant causes of morbidity and mortality 
amongst patients with diabetes. Development of novel treatments have been hampered by the lack 
of available animal models recapitulating the human disease. We hypothesized that experimental 
diabetes in rats combined with a cardiac or renal stressor, would mimic diabetic cardiomyopathy 
and nephropathy, respectively. Diabetes was surgically induced in male Sprague Dawley rats by 
90% pancreatectomy (Px). Isoprenaline (Iso, 1 mg/kg, sc., 10 days) was administered 5 weeks after 
Px with the aim of inducing cardiomyopathy, and cardiac function and remodeling was assessed by 
echocardiography 10 weeks after surgery. Left ventricular (LV) fibrosis was quantified by Picro Sirius 
Red and gene expression analysis. Nephropathy was induced by Px combined with uninephrectomy 
(Px-UNx). Kidney function was assessed by measurement of glomerular filtration rate (GFR) and 
urine albumin excretion, and kidney injury was evaluated by histopathology and gene expression 
analysis. Px resulted in stable hyperglycemia, hypoinsulinemia, decreased C-peptide, and increased 
glycated hemoglobin (HbA1c) compared with sham-operated controls. Moreover, Px increased heart 
and LV weights and dimensions and caused a shift from α-myosin heavy chain (MHC) to β-MHC gene 
expression. Isoprenaline treatment, but not Px, decreased ejection fraction and induced LV fibrosis. 
There was no apparent interaction between Px and Iso treatment. The superimposition of Px and 
UNx increased GFR, indicating hyperfiltration. Compared with sham-operated controls, Px-UNx 
induced albuminuria and increased urine markers of kidney injury, including neutrophil gelatinase-
associated lipocalin (NGAL) and podocalyxin, concomitant with upregulated renal gene expression of 
NGAL and kidney injury molecule 1 (KIM-1). Whereas Px and isoprenaline separately produced clinical 
endpoints related to diabetic cardiomyopathy, the combination of the two did not accentuate disease 
development. Conversely, Px in combination with UNx resulted in several clinical hallmarks of diabetic 
nephropathy indicative of early disease development.
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ANOVA  Analysis of variance
DbCM  Diabetic cardiomyopathy
DN  Diabetic nephropathy
EF  Ejection fraction
FITC  Fluorescein isothiocyanate
GFR  Glomerular filtration rate
GLUT  Glucose transporter
HbA1c  Glycated hemoglobin
Iso  Isoprenaline
KIM-1  Kidney Injury Molecule-1
LV  Left ventricular
LVAWd  Left ventricular anterior wall thickness in diastole
LVAWs  Left ventricular anterior wall thickness in systole
LVIDd  Left ventricular internal diameter in diastole
LVIDs  Left ventricular internal diameter in systole
LVPWd  Left ventricular posterior wall thickness in diastole
LVPWs  Left ventricular posterior wall thickness in systole
MHC  Myosin heavy chain
NGAL  Neutrophil gelatinase-associated lipocalin
OGTT  Oral glucose tolerance test
PAS  Periodic acid-Schiff
PDE3A  Phosphodiesterase 3A
Px  Pancreatectomy
SEM  Standard error of mean
SERCA  Sarco/endoplasmic reticulum  Ca2+-ATPase
sTNFR  Soluble tumor necrosis factor receptor
STZ  Streptozotocin
UNx  Uninephrectomy
UCP  Uncoupling protein
Diabetes is a global disorder presently affecting 463 million people worldwide and the prevalence is increasing 
at alarming  rates1. Moreover, diabetes is strongly associated with both cardiovascular and renal complications, 
which are significantly implicated in premature death among these  patients2,3. Long-term diabetes increases 
the risk of cardiovascular disease, including myocardial infarction, stroke, and  hypertension4–6. Independently, 
patients with diabetes also experience structural and functional abnormalities of the myocardium defined 
as diabetic cardiomyopathy (DbCM)7,8. The clinical manifestation of DbCM includes myocardial dilatation 
and hypertrophy, left ventricular (LV) dysfunction, and interstitial  fibrosis8–10. The underlying mechanism is 
still incompletely understood but aside from metabolic derangements, microvascular dysfunction has been 
 implicated7,11. Microvascular changes are also implicated in diabetic nephropathy (DN), which occurs in up 
to 40% of patients with diabetes. In addition to being associated with increased cardiovascular mortality, DN 
is also the leading cause of chronic and end-stage kidney  disease12. The main clinical manifestations of DN are 
persistent albuminuria and decreased glomerular filtration rate (GFR)13, while additional hallmarks include 
renal hypertrophy, loss of podocytes, glomerulosclerosis, and tubulointerstitial  fibrosis14,15. Nonetheless, DN is 
a heterogeneous kidney disease exhibiting variability in the degree of albuminuria, histopathological features, 
and different disease trajectories.
Further insight into the pathogenesis of both DbCM and DN is essential in order to advance clinical man-
agement of these major causes of morbidity and mortality worldwide. According to the Diabetic Complications 
Consortium, a valid rodent model of DbCM should include LV dysfunction and hypertrophy, interstitial fibrosis, 
and altered gene expression, but also an increased vulnerability to cardiac  stressors16. For DN, a valid model 
should comprise progressive albuminuria and GFR loss, alongside characteristic histopathological changes such 
as arteriolar hyalinosis, glomerulosclerosis, and tubulointerstitial  fibrosis17. The most-studied, current rodent 
models of diabetic complications are often limited in their usefulness as they produce only a few essential features 
associated with early stages of DbCM and DN  progression18–20. Some of these commonly-used models of diabetes, 
e.g. streptozotocin-treatment (STZ) and the db/db genetic mouse model, have previously been combined with 
angiotensin II or uninephrectomy to mimic and accelerate DbCM or DN,  respectively21–23.
The use of STZ in this context is however suboptimal, since the toxin also has the potential to induce direct 
nephrotoxic and cardiotoxic effects, independent of  hyperglycemia24–26. Pancreatectomy (Px), on the other hand, 
is a well-characterized method of surgically inducing diabetes in  rats27. An important advantage of this model is 
that it reflects the isolated effects of a reduced beta cell mass; immediately after surgery Px rats become insulin 
deficient and hyperglycemic, allowing full control of diabetic  onset28. To our knowledge, the cardiac and renal 
pathology has not previously been evaluated in the Px rat nor have models of DbCM and DN been superimposed 
upon this model. The aim of this study was therefore to investigate the development and progression of DbCM 
and DN in a Px rat model of diabetes. To accentuate the cardiac and renal changes, we combined Px with iso-
prenaline, a non-selective β-adrenoreceptor agonist and well-known cardiac stressor capable of inducing cardiac 
dysfunction and  fibrosis29–31, and uninephrectomy, which is known to accelerate the progression of injury in 
the remaining  kidney32,33. We hypothesized that superimposing these cardiac or renal stressors on pre-existing 
diabetes would result in rat models that recapitulated key features of human DbCM and DN, respectively.
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Materials and methods
Animals. Male Sprague–Dawley rats (NTac:SD) (8–10  weeks old, 210–280  g, Taconic Biosciences) were 
single-housed in a controlled environment (20–22 °C, humidity 40–60%) with a 12 h light/dark cycle. The ani-
mals were acclimatized for at least 1 week before surgery. All animals had ad  libitum access to regular chow 
diet (Altromin 1324, Brogaarden) and tap water throughout the study period. The studies were approved by 
The Danish Animal Experiments Inspectorate (license no. 2019-15-0201-01648, 2017-15-0201-01183, 2017-15-
0201-01286) and conformed to the European Parliament Directive on the Protection of Animals Used for Sci-
entific Purposes (2010/63/EU).
Experimental design. Three separate experiments were conducted in three cohorts of rats (Fig. 1). Experi-
ment 1 involved metabolic characterization of the Px rat model and included sham surgery (n = 10), 60% Px 
(n = 10), and 90% Px (n = 10). Experiment 2 evaluated the 90% Px and isoprenaline-treated rat as a model of 
DbCM, and included sham-vehicle (Sham-Veh, n = 10), Px-vehicle (Px-Veh, n = 15), sham-isoprenaline (Sham-
Iso, n = 12), and Px-isoprenaline (Px-Iso, n = 18) groups. Experiment 3 investigated the renal phenotype of the 
90% Px and uninephrectomized rat model of DN in sham-operated (n = 11) and Px and uninephrectomized 
rats (Px-UNx, n = 12). In experiments 2 and 3, only Px rats exhibiting fasted or fed blood glucose above 10 or 
12 mmol/L, respectively, 2 weeks post-Px were included.
Pancreatectomy. Rats were fasted overnight and received subcutaneous injections of atropine (0.1 mg/kg), 
enrofloxacin (50 mg/kg), carprofen (50 mg/kg) and saline (20 ml/kg) prior to surgery. All surgical interventions 
were performed under isoflurane anesthesia (2–3%). The rats were fasted until the next day, whereupon 5 g of 
chow was administered to each animal. Two days after surgery, the animals were fed ad libitum.
Pancreatectomy. Through a midline abdominal incision, the pancreatic tissue was removed by gentle abrasion 
with disposable micro-brushes (Plandent). All major blood vessels were left intact. For 60% Px, the tail and body 
of the pancreas were removed whereas the pancreatic tissue within the duodenal loop, comprising the entire 
head of the pancreatic tissue, was preserved. For 90% Px, only the pancreatic tissue between the common bile 
duct extending to the first loop of the duodenum was preserved.
Sham surgery. Through a midline abdominal incision, the tail and body of the pancreatic tissue was disengaged 
from the mesentery and gently manipulated before being repositioned to the abdominal cavity.
Figure 1.  Study design of experiment 1–3. GFR: glomerular filtration rate, Iso: isoprenaline, OGTT: oral 
glucose tolerance test, Px: pancreatectomy, Veh: vehicle, UNx: uninephrectomy.
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Isoprenaline treatment. Isoprenaline hydrochloride (Sigma-Aldrich) was dissolved in saline immediately 
prior to dosing and administered subcutaneously (1 mg/kg) for ten consecutive days beginning 5 weeks after 
sham surgery or 90% Px.
Uninephrectomy. Animals were subjected to uninephrectomy at the time of 90% Px. The right ureter, renal 
artery and vein were identified and ligated. Subsequently, the right kidney was removed. In sham-operated ani-
mals, the right kidney was exposed and gently manipulated.
Blood and plasma analyses. Blood glucose. Tail vein blood was collected once weekly from non-fasted 
or fasted (4 h) rats into heparinized glass capillary tubes and immediately suspended in glucose/lactate system 
solution buffer (EKF-diagnostics). The glucose concentration was measured immediately using a BIOSEN c-
Line glucometer (EKF-diagnostics) according to the manufacturer’s instructions.
Oral glucose tolerance test (OGTT). In experiment 1, animals were fasted for 4 h prior to oral glucose admin-
istration (2 g/kg body weight, 500 mg glucose/mL, Fresenius Kabi), and blood glucose was measured at 6 time-
points over the course of 240 min post-injection.
Blood and plasma markers. Plasma insulin and C-peptide were measured in duplicate using AlphaLISA plat-
form (Perkin Elmer) according to the manufacturer’s instructions. Glycated haemoglobin (HbA1c), plasma 
creatinine, and urea were measured using commercial assays (Roche Diagnostics) on the Cobas C-501 auto-
analyzer, and plasma cystatin C was measured using a commercial assay (R&D Systems) as per manufacturers’ 
instructions.
Urine collection and biochemical analyses. Rats were single-housed in metabolic cages (Techniplast) 
with free access to powdered chow and water. The excreted urine was collected for 16 h. Urine creatinine was 
quantified using a CREP2 assay (Roche Diagnostics) on the Cobas C-501 autoanalyzer as per manufacturer’s 
instructions. Urine albumin was measured using a rat albumin ELISA (Bethyl Laboratories). Urine neutrophil 
gelatinase-associated lipocalin (NGAL), soluble tumor necrosis factor receptors (sTNFR) I and II were meas-
ured using ELISA assays (R&D Systems), while urine nephrin and podocalyxin were quantified using ELISA 
assays from LSBio and CusaBio, respectively. All ELISA assays were run as per manufacturers’ instructions and 
levels of analytes were reported as the analyte-to-creatinine ratio (ACR) in urine. Urine ACR values were log10-
transformed before statistical analyses.
Echocardiography. Echocardiographic assessments were performed under isoflurane anesthesia (2–3%). 
After chest hair removal, the rats were positioned in supine position on a heated pad. Electrocardiogram elec-
trodes (lead II configuration, 3M) were placed and the rectal temperature was measured before and after exami-
nation. All examinations were performed using an ultrasound device (Philips, iE33) with a 12 MHz sector array 
probe. Function and dimensions of the LV were assessed from parasternal short and apical long axis views. 
The LV internal diameter (LVID), anterior and posterior wall thickness (LVAW, LVPW) were assessed in sys-
tole (LVIDs, LVAWs and LVPWs, respectively) and diastole (LVIDd, LVAWd and LVPWd, respectively) using 
2D-guided M-mode in a short axis view at the level of the papillary muscles, according to the leading edge to 
leading edge  principle34. The ejection fraction (EF) was calculated using the Teichholz  formula35. To correct for 
the difference in LV size, all short axis measurements were normalized to body weight. LV filling (E and A veloc-
ity and deceleration time) was measured in the apical 4-chamber long axis view with the sample volume placed 
at the tip of the mitral valve leaflets using pulsed wave Doppler. Echocardiographic analyses were performed 
offline using Q-station software (version 3.8.5, Philips). Image acquisitions and analyses were performed by one 
operator blinded towards identity of the animals.
Glomerular filtration rate measurement. GFR was assessed by a fluorescein isothiocyanate (FITC)-
inulin test. Briefly, a 5% solution of FITC-inulin (TdB Consultancy) was prepared in 0.85% saline by heating 
and overnight dialysis using a Spectra/Por 6 dialysis tube (1 kDa molecular cut-off; Spectrum Labs). The FITC-
inulin solution was sterile filtered (0.2 µm syringe filter) before tail vein injections in conscious rats (100 mg/kg). 
Sublingual blood was collected in heparinized tubes at 8 timepoints over the course of 75 min post-injection. 
Plasma FITC-inulin concentrations were measured using a plate-reader (CLARIOstar, BMG LABTECH) and 
GFR was calculated using a two-compartment model from the rate of decay in plasma FITC-inulin as described 
 previously36 and normalized to body weight.
Histology and stereology. Pancreas. At termination, pancreatic samples from sham, 60% and 90% Px 
rats were removed en-bloc and incubated in 10% neutral buffered formalin until further processing. Pancreatic 
tissue was carefully dissected, weighed, and processed as previously  described37. Briefly, pancreas was rolled 
tightly into strips of gauze before infiltration with paraffin in an automated tissue processor (VIP5, Sakura). 
The pancreas was then cut into 7–9 systematic uniform random tissue slabs with a razor blade fractionator 
and embedded in paraffin blocks with the cut surface down. Subsequently, 5 µm thick sections were cut from 
each block on a microtome and collected on microscope slides. Immunohistochemistry against beta cells and 
non-beta cells were performed as a double staining using standard procedures. Briefly, after deparaffinization 
and microwave oven pretreatment in Tris-EGTA buffer (pH 9), sections were stained for non-beta cells using 
an antibody cocktail consisting of rabbit anti-glucagon (Phoenix, H-028–02, 1:5000), rabbit anti-somatostatin 
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(Dako, 0566, 1:7500), and rabbit anti-pancreatic polypeptide (Europroxima, B32-1, 1:5000). The antibody cock-
tail was detected using Envision + anti-rabbit HRP-coupled polymer system (Dako, K4002) and developed with 
DAB-Nickel as chromogen. Next, beta cells were stained using a guinea pig anti-insulin antibody (Dako, A0564, 
1:6000) followed by a biotinylated secondary donkey anti-guinea pig antibody (Jackson ImmunoResearch 706-
065-148, 1:2000). Amplification and development of the insulin staining was performed using the Vectastain 
ABC elite kit (Vector Laboratories PK6100) and Impact NovaRed (Vector Laboratories, SK-4805). Finally, sec-
tions were counterstained with Mayer’s hematoxylin (Sigma-Aldrich).
Heart and kidney. One half of the sagittally-divided LV or left kidney were fixed in 10% neutral buffered for-
malin for 24 h at room temperature. The fixed tissues were cut into 5–7 systematic uniform random tissue slabs 
with a razor blade fractionator and embedded in paraffin blocks with the cut surface down. For Picro Sirius Red 
staining, a set of 3 µm sections were cut on a microtome from each block and collected on microscope slides. For 
Periodic acid-Schiff (PAS) staining, another set of sections were cut in pairs with a dissector distance of 30 µm. 
Picro Sirius Red staining: After deparaffinization, sections were incubated in Wiegert’s iron hematoxylin (Sigma-
Aldrich) and then stained in Picro Sirius Red (Sigma-Aldrich) before they were cover slipped with Pertex. PAS 
staining: sections were deparaffinized and oxidized with 0.5% periodic acid solution followed by incubation with 
Schiff ’s reagent. Sections were counterstained in Mayer’s hematoxylin and cover slipped with Pertex. Podocin/
type IV collagen double fluorescent immunohistochemical staining of kidney sections was performed as previ-
ously  described22.
Image analysis and stereological quantification. Stereological quantification of beta cell and non-beta cell mass 
was calculated as an area fraction (area of beta cells versus total pancreatic area) multiplied by the dissected 
pancreas mass as previously  described37. Heart and kidney collagen content was determined as Picro Sirius Red 
area fraction using image analysis. Stained slides were scanned under a 20 × objective in an Aperio Scanscope 
AT slide scanner and imported into an image analysis module in Visiopharm Integrator System (Visiopharm). A 
Bayesian classifier was trained to detect Picro Sirius Red positive collagen versus other tissue components. The 
collagen area fraction was calculated as the Picro Sirius Red area divided by the total tissue area. Intra-glomer-
ular collagen type 4 content and stereological estimation of kidney compartmental volumes were determined as 
previously  described22. The mean glomerular volume was calculated as total glomerular volume divided by the 
mean number of glomeruli estimated using the physical dissector on serially cut reference and look-up sections 
with a dissector distance of 30 µm38.
RNA sequencing. Transcriptome analysis was performed by sequencing of RNA extracts from LV tissue 
and renal cortex. RNA was purified from homogenized tissue using the NucleoSpin RNA Plus kit (Macherey-
Nagel GmbH). The RNA quantity was measured using Qubit (Thermo Scientific, Eugene, OR) and RNA quality 
was determined using a bioanalyzer with RNA 6000 Nano kit (Agilent). Purified RNA from each sample was 
used to generate a single end cDNA library using the NEBNext Ultra II Directional RNA Library Prep Kit for 
Illumina (New England Biolabs, Ipswich, MA). cDNA libraries were sequenced on a NextSeq 500 using Next-
Seq 500/550 High Output Kit V2 (Illumina) for 75 cycles to a depth of 14–28 million reads per sample. Reads 
were aligned to the Ensembl Rnor_6.0 release 89 Rattus norvegicus genome using STAR v.2.5.2a with default 
 parameters39.
Statistical analysis. Except for the gene expression data set, which was analysed using DEseq2 package 
for R with default  parameters40, all data were analyzed using GraphPad Prism software (version 8.2). Normal 
distribution of data was assessed by inspection of QQ plots and by using the Shapiro–Wilk test. Normally dis-
tributed data are shown as mean ± standard error of mean (SEM). In experiment 1, repeated measures two-way 
analyses of variance (ANOVA) with Bonferroni’s post-hoc test were used for time-course data and one-way 
ANOVA with Tukey’s post-hoc test was used for insulin and beta cell mass data. In experiment 2, two-way 
ANOVA was applied and in addition to evaluating the main effects of Px and isoprenaline treatment, the inter-
action between the two was included to evaluate a potential synergistic effect. Main effects of Px or isoprenaline 
were reported when no interaction between these two was found. Unpaired t-test and repeated measurements 
two-way ANOVA with Bonferroni’s Multiple Comparisons test were used in experiment 3. A p value < 0.05 was 
considered statistically significant.
Ethics approval and consent to participate. The animal experiments were approved by The Danish 
Animal Experiments Inspectorate (license no. 2019-15-0201-01648, 2017-15-0201-01183, 2017-15-0201-01286) 
and conformed to the European Parliament Directive on the Protection of Animals Used for Scientific Purposes 
(2010/63/EU).
Consent for publication. All authors have declared their consent for this publication.
Results
Metabolic characterization of the pancreatectomized rat. In experiment 1, 60% Px did not affect 
body weight, whereas 90% Px resulted in a lower rate of body weight gain over 6 weeks compared with sham-
operation (p < 0.05, Fig. 2A). One week after surgery, 90% Px rats exhibited hyperglycemia (non-fasting blood 
glucose > 10 mmol/L) whereas 60% Px and sham rats were normoglycemic (p < 0.05, Fig. 2B). Among the 90% 
Px rats, 50% remained hyperglycemic throughout the 6-week study period (defined as ‘90% Px responders’) 
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whereas 50% returned to normoglycemia 3 weeks after surgery (defined as ‘90% Px non-responders’). Corre-
spondingly, blood glucose was increased for 15–120 min after an oral glucose bolus during the OGTT in 90% Px 
responders compared to sham (p < 0.05, Fig. 2C), but only for 15–30 min in 90% Px non-responders and in 60% 
Px. Both 60% and 90% Px resulted in significantly lower plasma insulin compared with sham (p < 0.05, Fig. 2D). 
While the total beta cell mass in the remaining pancreatic tissue was reduced in 60% and 90% Px rats compared 
to sham-operated controls 6 weeks after surgery (p < 0.01 and p < 0.001, respectively, Fig. 2E), morphology of the 
individual islets looked similar across groups (Fig. 2F).
The pancreatectomized and isoprenaline-treated rat as a model of DbCM. In experiment 2, one 
rat was excluded due to lack of hyperglycemia 2 weeks after Px, five rats died from post-operative complications, 
and five Sham-Iso rats died after the first administration of isoprenaline (isoprenaline-induced mortality rate: 
29.4%).
No significant interaction between Px and isoprenaline treatment was found for any investigated outcome. 
Instead, irrespective of isoprenaline treatment, a main effect of Px was found for several measures reflecting glu-
cose metabolism and LV remodeling. Specifically, HbA1c was increased post-Px, plasma C-peptide and insulin 
were decreased, and animals subjected to Px did not gain body weight to the same extent over the following 
10 weeks as sham-operated animals (Table 1; all p < 0.001). Heart rate and peak E wave velocity were decreased 
(Table 2; p < 0.001) and relative heart and LV weight (p < 0.05), wall thickness and internal dimensions in systole 
and diastole (Fig. 3, Table 2; p < 0.001) were increased in Px rats compared with sham-operated counterparts. 
Furthermore, LV collagen area fraction was modestly decreased by Px (Fig. 3; p < 0.05). Owing to the frequent 
finding of fused E- and A-waves, calculation of E/A ratios was not possible during echocardiography.
In contrast to Px, isoprenaline treatment decreased indices of systolic LV function (LVIDs and EF) (Fig. 3, 
Table 2; both p < 0.001) and increased LV collagen area fraction (Fig. 3, p < 0.001).
Transcriptome analysis of LV tissue revealed a Px-driven change in expression of genes related to cardiac 
metabolism and function compared to sham. Specifically, glucose transporter (GLUT) 1, GLUT4, α-myosin heavy 
chain (MHC), and sarco/endoplasmic reticulum  Ca2+-ATPase (SERCA)-2 were all downregulated, whilst β-MHC 
and uncoupling protein (UCP) 3 were upregulated (p < 0.001, Fig. 4). In contrast, isoprenaline treatment per se 
did not affect expression of these selected genes compared to vehicle treatment other than upregulating GLUT1 
(p < 0.01). Further analysis of expression levels of genes involved in adrenergic signaling revealed that β2-receptors 
were downregulated by Px (p < 0.01) while β1-receptors were unaffected (Supplementary Fig. S1). Moreover, 
expression of downstream mediators of β-receptor signaling, adenylate cyclase (AC) 6 and phosphodiesterase 
Figure 2.  Body weight, blood glucose, plasma insulin, and beta cell mass for pancreatectomized animals. Body 
weight (A) and non-fasting blood glucose (B) measured in rats subjected to pancreatectomy (Px), where either 
60% Px or 90% Px was removed, or sham surgery throughout the study period. Blood glucose levels from an 
oral glucose tolerance test performed 3 weeks after surgery (C). Non-fasting plasma insulin and total beta-cell 
mass determined by stereology 6 weeks after surgery (D, E) and representative images of sections from sham 
and Px rats stained for beta cells (orange-brown; insulin-immunoreactive) and non-beta cells (black; pancreatic 
polypeptide, somatostatin and glucagon-immunoreactive) (F). Data is presented as mean + SEM. n = 10, 10, 5, 5. 
Two-way ANOVA with Bonferroni’s post-hoc test was applied to blood glucose data and one-way ANOVA with 
Tukey’s post-hoc test to insulin and beta cell mass data. *p < 0.05; **p < 0.01; ***p < 0.001 vs Sham. Graphs are 
generated using GraphPad Prism (v 8.2), https ://www.graph pad.com.
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3A (PDE3A) were upregulated by Px (p < 0.001 and p < 0.05, respectively) while PDE3A was downregulated by 
isoprenaline (p < 0.05, Supplementary Fig. S1).
The pancreatectomized and uninephrectomized rat as a model of DN. In experiment 2, renal 
changes induced by Px were observed including increased left kidney weight (Table  1, p < 0.05) and urine 
albumin-to-creatinine ratio (2549 ± 1447 µg/mg vs. 64 ± 10 µg/mg, p < 0.01) in Px-Veh compared to Sham-Veh 
10 weeks after surgery. This indicates presence of modest renal pathology in the Px rats and we therefore con-
ducted a pilot study to investigate if UNx, a known accelerator of disease progression in rodent models of DN, 
exacerbated renal changes in Px rats. Here, we found that UNx increased urine markers of kidney injury (i.e. 
albumin and NGAL), kidney and glomerular hypertrophy, and glomerular collagen 4 in Px rats (see Supple-
mentary Fig. S2). Subsequently in experiment 3, the progression of DN in Px rats was investigated in conjunc-
tion with UNx and compared to sham operated, age-matched rats. As expected, Px-UNx caused an increase in 
blood glucose and a decrease in plasma insulin compared to sham (both p < 0.05, Table 3). Furthermore, relative 
heart weight was increased in Px-UNx compared to sham (p < 0.001, Table 3). Urinary excretion of albumin, 
NGAL, and sTNFR-II was increased in Px-UNx 2 weeks after surgery and was sustained at 6 and 9 weeks post-
surgery (all p < 0.001, Table 4). Urine sTNFR-I and podocalyxin excretion was increased by week six and nine 
after surgery (both p < 0.001). At termination, 11 weeks after surgery, plasma urea was increased in Px-UNx 
(p < 0.05), whereas plasma creatinine was reduced (p < 0.05). Cystatin C was not significantly different, but GFR 
was increased 8 weeks after surgery in Px-UNx compared to sham (p < 0.05). 
Renal hypertrophy was observed in Px-UNx rats compared with sham-operated animals with increased 
kidney weight and renal cortex and medulla volumes (p < 0.05, Fig. 5A–C). Px-UNx rats also displayed significant 
Table 1.  Baseline and terminal characteristics of pancreatectomized and isoprenaline treated rats. 
Measurements were performed at pre-surgery and/or 10 weeks after sham surgery or pancreatectomy (Px) in 
vehicle (Veh)- or isoprenaline (Iso) treated rats. Data is presented as mean ± SEM. Two-way ANOVA; main 
effect of pancreatectomy *p < 0.05; ***p < 0.001, main effect of isoprenaline  treatment###p < 0.001.
Sham-Veh (n = 10) Px-Veh (n = 15) Sham-Iso (n = 12) Px-Iso (n = 18) Main effect
Body weight (g, pre-surgery) 249 ± 5 253 ± 3 247 ± 6 248 ± 3 ns
Body weight (g, week 10) 454 ± 10 293 ± 11 447 ± 12 297 ± 10 ***
Blood glucose (mmol/L, pre-surgery) 3.3 ± 0.2 3.6 ± 0.2 3.4 ± 0.1 3.4 ± 0.1 ns
Blood glucose (mmol/L, week 10) 4.8 ± 0.1 24.7 ± 1.0 4.7 ± 0.2 22.4 ± 1.5 ***
Plasma insulin (pg/mL, week 10) 835 ± 96 180 ± 25 755 ± 87 173 ± 23 ***
C-peptide (pg/mL, week 10) 2805 ± 105 839 ± 110 3012 ± 198 697 ± 70 ***
HbA1c (%, week 10) 3.8 ± 0.1 9.2 ± 0.4 4.3 ± 0.5 10.0 ± 0.2 ***
Heart weight (mg, week 10) 1459 ± 92 1259 ± 67 1206 ± 72 1244 ± 58 ns
Relative heart weight (mg/g body weight, 
week 10) 3.2 ± 0.2 4.2 ± 0.3 2.7 ± 0.1 4.2 ± 0.3 ***
Left ventricular weight (mg, week 10) 966 ± 48 725 ± 30 1020 ± 36 760 ± 37 ***
Relative left ventricular weight (mg/g body 
weight, week 10) 2.2 ± 0.1 2.4 ± 0.1 2.3 ± 0.1 2.5 ± 0.1 *
Kidney weight (mg, week 10) 1443 ± 50 1723 ± 77 1463 ± 79 1593 ± 88 *
Relative kidney weight (mg/g body weight, 
week 10) 3.1 ± 0.1 5.6 ± 0.2 3.4 ± 0.3 5.3 ± 0.2 ***
Table 2.  Echocardiographic assessment of left ventricular morphology and function in pancreatectomized 
and isoprenaline treated rats. Left ventricular wall thickness, filling parameters and heart rate ten weeks 
after sham surgery or pancreatectomy (Px) in vehicle (Veh)- or isoprenaline (Iso) treated rats. Heart rate was 
measured during echocardiography in week 10. Data is presented as mean ± SEM. Two-way ANOVA; main 
effect of pancreatectomy **p < 0.01; ***p < 0.001, main effect of isoprenaline  treatment#p < 0.05.
Sham-Veh (n = 10) Px-Veh (n = 15) Sham-Iso (n = 12) Px-Iso (n = 18) Main effect of Px or Iso
Relative LVAWd (mm/mg BW) 3.5 ± 0.3 5.1 ± 0.4 3.6 ± 0.2 4.8 ± 0.3 ***
Relative LVPWd (mm/mg BW) 3.3 ± 0.3 4.4 ± 0.2 3.1 ± 0.2 4.2 ± 0.2 ***
Relative LVAWs (mm/mg BW) 6.3 ± 0.3 8.9 ± 0.5 5.9 ± 0.3 7.6 ± 0.4 ***#
Relative LVPWs (mm/mg BW) 5.7 ± 0.4 6.9 ± 0.3 4.6 ± 0.3 6.3 ± 0.3 ***#
Peak E wave velocity (cm/s) 114 ± 3 107 ± 4 123 ± 5 104 ± 4 **
Deceleration time (ms) 42 ± 2 47 ± 5 41 ± 3 42 ± 3 ns
Heart rate (bpm) 368 ± 3 299 ± 8 373 ± 3 281 ± 18 ***
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glomerular hypertrophy as assessed by stereology (p < 0.05 vs. sham, Fig. 5D), in an unaltered number of glomer-
uli (39,472 ± 1336 vs 39,130 ± 1665 glomeruli, ns.). Fibrosis quantification by histopathology showed unchanged 
levels of renal collagen (Fig. 5E, F), and the area fraction of type IV collagen in the glomeruli was unaffected in 
Px-UNx rats compared with sham (Fig. 5G, H).
Renal cortex gene expression analysis of selected pathways involved in the pathogenesis of DN is shown 
in Fig. 6A. Several genes involved in TGF-beta signaling, fibrosis and inflammation, and angiogenesis were 
upregulated, while the expression of genes involved in the renin–angiotensin–aldosterone system was down-
regulated (Fig. 6A). Genes of the insulin signaling pathway were significantly altered in Px-UNx compared to 
sham (Fig. 6A). Expression of podocyte markers was either down-regulated (nephrin) or unchanged (podocin), 
while tubular damage markers [neutrophil gelatinase-associated lipocalin (NGAL) and Kidney Injury Molecule-1 
(KIM-1)] were significantly upregulated (p < 0.05, Fig. 6B). Finally, drug-related targets including sodium-glucose 
transport protein 2, glucagon-like peptide 1 receptor, and angiotensin I converting enzyme were differentially 
regulated in Px-UNx compared to sham (Fig. 6B).
Figure 3.  Echocardiographic and histological assessment of left ventricular (LV) morphology and function 
in pancreatectomized and isoprenaline treated rats. Echocardiographic parasternal short-axis views were used 
to obtain M-mode images at the level of the papillary muscles (A). LV ejection fraction (B) and end-diastolic 
and -systolic diameters (LVIDd, LVIDs) normalized to body weight (C, D), and collagen area fraction (E) were 
evaluated 10 weeks after sham surgery or pancreatectomy (Px) in vehicle (Veh)- or isoprenaline (Iso) treated 
rats. Representative images of Picro Sirius Red stained LV cross sections (F). Data is presented as mean + SEM. 
n = 10,15,12,18. Two-way ANOVA; main effect of pancreatectomy ***p < 0.001, main effect of isoprenaline 
 treatment###p < 0.001. Graphs are generated using GraphPad Prism (v 8.2), https ://www.graph pad.com.
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Discussion
Here we characterized two preclinical rat models of DbCM and DN by superimposing isoprenaline treatment 
and UNx, respectively, on Px. Px led to marked alterations in glucose homeostasis and induced morphological 
and functional changes related to cardiovascular and renal endpoints. While no synergistic effect was revealed 
by superimposing the cardiac stressor, isoprenaline, to Px, superimposing UNx to Px in rats led to exacerbated 
DN as measured by alterations in albuminuria and GFR.
In agreement with previous  findings41, we demonstrated that 90%, but not 60%, Px induced permanent, stable 
hyperglycemia, concomitant with a surgically induced reduction in beta cell mass and thereby lower plasma insu-
lin levels. Interestingly, we found that despite having undergone 90% Px, normoglycemia was restored 3 weeks 
after surgery in a subset (50%) of rats, termed non-responders, in experiment 1. These rats were able to maintain 
Figure 4.  Expression of selected genes in the left ventricle determined by RNA sequencing of 
pancreatectomized and isoprenaline treated rats. Expression levels of genes relevant for cardiac function 
10 weeks after sham surgery or 90% pancreatectomy (Px) in vehicle (Veh)- or isoprenaline (Iso) treated rats. 
Data is presented as mean + SEM. n = 7,8,8,8. Two-way ANOVA; main effect of pancreatectomy ***p < 0.001, 
main effect of isoprenaline treatment ##p < 0.01. GLUT: glucose transporter, MHC: myosin heavy chain. SERCA: 
sarco/endoplasmic reticulum  Ca2+-ATPase, UCP: Uncoupling protein. Graphs are generated using GraphPad 
Prism (v 8.2), https ://www.graph pad.com.
Table 3.  Terminal characteristics of pancreatectomized-uninephrectomized rats. Glomerular filtration rate 
was measured eight weeks after surgery. Body and heart weight, and blood and plasma levels at eleven weeks in 
sham operated or pancreatectomized-uninephrectomized (Px-UNx) rats. Data are presented as mean ± SEM. 
Unpaired t test; *p < 0.05; **p < 0.01; ***p < 0.001 vs. Sham.
Sham (n = 12) Px-UNx (n = 11)
Glomerular filtration rate (ml/min/kg) 6.6 ± 0.3 8.2 ± 0.3 **
Body weight (g) 450 ± 3 306 ± 4 ***
Blood glucose (mmol/L) 4.8 ± 0.1 26.2 ± 1.8 ***
Insulin (pg/mL) 782 ± 102 193 ± 58 ***
Urea (mmol/L) 5.5 ± 0.2 9.4 ± 0.7 ***
Creatinine (µmol/L) 23.5 ± 0.6 21.2 ± 0.7 *
Cystatin C (ng/mL) 2373 ± 50 2370 ± 56 ns
Relative kidney weight (mg/g body weight) 3.2 ± 0.0 9.3 ± 0.1 ***
Relative heart weight (mg/g body weight) 2.8 ± 0.0 3.3 ± 0.0 ***
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adequate insulin production to support normoglycemia. Hereafter, the Px procedure was further refined, which 
resulted in a reduction to 2% of non-responders in subsequent studies. Evidently, a certain threshold in critical 
beta cell mass exists rendering a meticulous use of anatomical landmarks during removal of pancreatic tissue 
a necessity.
Besides demonstrating a pronounced and sustained diabetic phenotype, including decreased C-peptide as well 
as increased HbA1c, the Px rat also exhibited mild cardiac hypertrophy and remodeling indicated by increased 
relative heart and LV weights, LV wall thickness and LVIDd. Although EF was preserved, early systolic dysfunc-
tion was revealed by increased LVIDs. In DbCM, diastolic dysfunction is known to precede systolic dysfunction 
but, in this study, unfortunately, several indices of diastolic function, including the peak velocity of the late filling 
of the LV, could not be derived due to low temporal resolution and thus E/A fusion during the echocardiographic 
examination. Although the LV filling pattern could not be fully evaluated, the finding of a decreased early filling, 
corresponding to the peak E wave mitral inflow velocity, may be indicative of impaired relaxation and thus early 
diastolic dysfunction in Px rats. Furthermore, Px intervention altered the expression of selected genes involved 
in the pathogenesis of DbCM as suggested by the Diabetes Complications  Consortium16. For instance, the major 
cardiac glucose transporter, GLUT4, was downregulated in Px. Interestingly, impaired insulin signaling, including 
decreased recruitment of GLUT4 to the plasma membrane, has been implicated in promoting cardiomyocyte 
stiffness in the diabetic  heart42. In support of an attenuated contractile function, a shift from the ‘fast’ isoform 
α-MHC to the slower β-MHC along with decreased SERCA-2 expression was found in LV tissue.
An important advantage of the Px model is that it reflects the isolated effects of reduced beta cell mass, with-
out the potential multiple-organ toxic effects of  STZ24 or the confounding effects of obesity and impaired leptin 
signaling found in e.g. ZDF rats. A disadvantage, however, is that not only beta cells, but also exocrine acinar 
cells are excised during 90% Px. The lack of pancreatic enzymes following  Px43 may thus act as a confounder by 
potentially inducing malnutrition and growth retardation. In future studies, supplementation with pancreatic 
enzymes may therefore be considered to avoid such potential effects.
Isoprenaline is a β-adrenergic agonist promoting cardiac hypertrophy, fibrosis, and systolic dysfunction in rats 
when administered in supraphysiological  dosages31,44,45. In the present study, isoprenaline treatment per se did 
not induce cardiac hypertrophy or remodeling but did induce increased LV fibrosis and reduced systolic function. 
A possible explanation for the lack of isoprenaline-induced LV hypertrophy is that the cardiac remodeling may 
be reversible as indicated previously by Golomb et al.46, demonstrating reversal just seven days after cessation of 
isoprenaline. In the present study, LV changes were assessed nearly 4 weeks after isoprenaline treatment and in 
comparison to previous studies where a single high-dose regimen has been  used30,44, a relatively low isoprenaline 
dosage was applied.
Clinical studies of patients with diabetes have previously shown an increased susceptibility to hemodynamic 
 stressors47,48 and we thus hypothesized that the cardiac changes induced by isoprenaline would be accelerated 
and accentuated when superimposed on Px. Unexpectedly, the combination of Px and isoprenaline treatment did 
not accentuate or accelerate LV morphological or functional changes but it cannot be excluded that molecular 
changes indicative of DbCM have been induced in this model.
Isoprenaline induced a nearly 30% mortality rate in sham-operated rats after the first exposure, whereas 
no isoprenaline-related deaths were observed in Px animals. Mortality following isoprenaline treatment has 
been reported previously using higher doses in non-diabetic  rats30,31,44. In the present study, the expression of 
β2-receptors was slightly downregulated by Px whilst PDE3A was upregulated, which could attenuate respon-
siveness to β-receptor stimulation by  isoprenaline49, and hence partly explain the lack of synergy, but also the 
increased mortality rate. Conversely, AC6, known to improve cardiac function and responsiveness to β-receptor 
 stimulation50, was upregulated by Px. Another explanation could be related to the decreased heart rate in Px 
rats. Lower heart rates will have longer refractory periods and this phenomenon could perhaps protect against 
isoprenaline-induced tachycardia and arrhythmias. However, further experiments are needed to elucidate this 
subject further.
UNx is known to accelerate DN progression in  rodents18, which we confirmed in our DN pilot study, and, 
importantly, we observed that the combination of Px and UNx induced several hallmarks of DN. Px-UNx rats 
displayed profound renal and glomerular hypertrophy, which together with increased GFR are indicative of 
Table 4.  Urine markers in pancreatectomized-uninephrectomized and sham rats. Measurements were 
performed after two, six, and nine weeks in sham operated or pancreatectomized-uninephrectomized 
(Px-UNx) rats. Data is presented as mean ± SEM. Two-way repeated measures ANOVA with Bonferroni’s 
Multiple Comparisons post-hoc test; **p < 0.01; ***p < 0.001 vs. Sham.
Week 2 Week 6 Week 9
Sham (n = 12) Px-UNx (n = 11) Sham (n = 12) Px-UNx (n = 11) Sham (n = 12) Px-UNx (n = 11)
Creatinine (µmol/L) 7197 ± 661 993 ± 209 *** 8189 ± 444 606 ± 85 *** 8273 ± 445 520 ± 65 ***
Albumin-to-creatinine (µg/mg) 109 ± 13 1250 ± 653 *** 207 ± 60 10,281 ± 6239 *** 370 ± 170 13,473 ± 7619 ***
NGAL-to-creatinine (µg/mg) 3.27 ± 0.8 16.6 ± 2.2 *** 3.84 ± 0.4 14.9 ± 1.7 *** 2.69 ± 0.4 13.3 ± 1.9 ***
Podocalyxin-to-creatinine (µg/
mg) 19.9 ± 2.7 76.2 ± 9.3 14.6 ± 1.8 186.9 ± 59.3 *** 11.8 ± 2.0 195.2 ± 41.9 ***
sTNFR-I- to-creatinine (pg/mg) 36.0 ± 3.4 259 ± 32 23.6 ± 1.4 427 ± 117 *** 21.3 ± 1.3 447 ± 133 ***
sTNFR-II-to-creatinine (pg/mg) 2521 ± 197 5212 ± 413 *** 1460 ± 122 3520 ± 391 *** 1348 ± 163 2743 ± 414 **
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renal hyperfiltration. These phenomena are also observed in patients during the early phase of DN disease 
 progression51. Importantly, Px-UNx animals presented with persistent albuminuria detectable as early as 2 weeks 
post-surgery. Similarly, urine NGAL excretion was increased, which is indicative of tubular damage and sup-
ported by increased RNA expression levels of the clinical biomarkers, NGAL and KIM-152,53. Urine sTNFR I 
and II excretion was increased; a finding that corresponds to reports of diabetic patients with diabetic kidney 
 disease54. Finally, urine podocalyxin excretion was increased in line with observations of early podocyte injury 
in human  patients55.
Although expression of genes involved in kidney fibrosis and inflammation (incl. extracellular matrix genes 
and TGF-beta signaling) was increased in the renal cortex of Px-UNx rats, histopathological evaluation of kidneys 
Figure 5.  Renal morphometric and histopathological characteristics in pancreatectomized-uninephrectomized 
rats. Measurements were performed 11 weeks after sham or pancreatectomy-uninephrectomy (Px-UNx). 
Kidney weight and volume of renal compartments (A-D). Representative images of Picro Sirius Red (PSR) 
stained kidney sections and total renal fibrosis quantification (E–F). Representative images of kidney sections 
stained for co-localization type IV collagen (yellow) and podocin (green), and quantification of intra-glomerular 
type IV collagen (white) (G-H). Data is presented as mean + SEM. n = 12,11. Unpaired t test; ***p < 0.001 vs. 
sham. Graphs are generated using GraphPad Prism (v 8.2), https ://www.graph pad.com.
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from the Px-UNx model did not reveal evidence of renal fibrosis or glomerulosclerosis as measured by intra-
glomerular type IV collagen. On the contrary, stereological assessment of the kidney revealed massive renal and 
glomerular hypertrophy. Together with the measured GFR, these data demonstrate that the Px-UNx rat repre-
sents a model of early stage DN in human patients. Longer term studies, beyond the 10 weeks reported here, are 
likely required for progression of DN with resulting GFR loss, glomerulosclerosis, and tubulointerstitial fibrosis.
Renal gene expression in the Px-UNx rat showed significant induction of genes associated with fibrosis 
(incl. collagen 1a1, collagen 4a1, and Lamc2), TGF-beta signalling (incl. Grem1, TGF-beta 1 and 2), inflamma-
tion (incl. CD68 and ICAM1), and injury markers (incl. Havcr1 and Lcn2) reflecting the pro-fibrotic and pro-
inflammatory milieu in the kidney of Px-UNx rats. Furthermore, expression of podocyte markers, Nphs1 and 
Nphs2, was reduced or not regulated in Px-UNx indicating that the loss of podocytes is limited in this model 
and supporting the notion that Px-UNx rats display features of early stage DN. Furthermore, the expression of 
drug-related target genes was also investigated and showed increased expression of SGLT2 in the diabetic kidney 
in line with findings in other rodent models of  DN56. On the other hand, expression of GLP-1R was unaffected 
in Px-UNx. This is contradictory to findings in the STZ-induced diabetic mouse, where GLP-1R gene expres-
sion is found to be reduced in the  glomerulus57. This discrepancy may be explained by the fact that the analysis 
of gene expression in experiment 3 was conducted by sequencing renal cortex RNA, and gene expression levels 
thus represent an average of the expression across glomerular, tubular, vascular and interstitial compartments. 
Seeing that glomeruli make up only approximately 1% of the total kidney volume in diabetic, uninephrecto-
mized  mice58, transcriptional changes of a gene in one compartment (e.g. the glomerulus) may thus be masked 
for genes expressed in more than one compartment such as e.g. GLP-1R. The ACE and ACE2 expression data 
underscores this notion; we show that cortical expression of ACE and ACE2 is decreased in Px-UNx, whereas 
compartmentalized gene expression analysis show increased expression of ACE and ACE2 in glomeruli and 
decreased expression in the tubulointerstitium and whole kidneys in STZ-induced diabetes in  rats59.
Interestingly, in experiment 3, we found that the relative weight of the heart was increased almost 18% in 
Px-UNx rats compared to sham. Seeing that Px alone increased the weight of the left ventricle by only 9% this 
could be indicative of cardiorenal syndrome. However, cardiac changes in our DN model were beyond the scope 
of the present study, but a topic worth pursuing in a future study.
Figure 6.  Renal gene expression determined by RNA sequencing in pancreatectomized-uninephrectomized 
rats. Measurements were performed at termination, 11 weeks after sham or pancreatectomy-uninephrectomy 
(Px-UNx) on RNA isolated from renal cortex. Pathway summary presenting selected genes that are significantly 
regulated in the renal cortex of Px-UNx vs. Sham animals at p < 0.01 significance level (A). Expression levels of 
selected genes in the renal cortex (B). Data are mean + SEM. n = 12,11. Unpaired t test; **p < 0.01; **p < 0.001 
vs Sham after correction for gene-wise multiple testing. ACE: Angiotensin I converting enzyme, ANGR1a: 
Angiotensin II receptor, type 1a, GLP1R: Glucagon-like peptide 1 receptor, KIM-1: kidney injury molecule 
1, NGAL: neutrophil gelatinase-associated lipocalin, RAAS: renin–angiotensin–aldosterone system, SGLT2: 
Sodium-glucose transport protein 2. Graphs are generated using ggplot2 in R (v 3.3.2), https ://www.r-proje 
ct.org and GraphPad Prism (v 8.2), https ://www.graph pad.com.
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Although non-diabetic uninephrectomized animals were not included as a control in this study, our data 
suggest that UNx accelerates DN in the Px rat. Compared with Px rats from experiment 2, UNx-Px rats displayed 
augmented urine ACR in experiment 3. This suggests that kidney injury is accelerated in Px-UNx compared 
with Px alone.
conclusion
In conclusion, 90% Px in the rat resulted in a robust model of experimental diabetes with a surgically induced 
onset of hyperglycemia concomitant with hypoinsulinemia. The observation of increased LV wall thickness 
and internal diameters indicated that Px may mimic early stages of DbCM disease development. The preclini-
cal applicability was supported by changes in expression levels in genes centrally involved in cardiomyocyte 
changes related to DbCM. However, the combination of isoprenaline and Px did not further accentuate DbCM 
development. Px in combination with UNx exhibited pronounced albuminuria, renal and glomerular hypertro-
phy together with increased GFR resembling features of early stage DN. The Px and the Px-UNx models could 
therefore be useful to study the potential efficacy of new therapeutic interventions for attenuating early disease 
progression in DbCM and DN, respectively.
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All data and materials are available upon request.
Received: 6 May 2020; Accepted: 10 September 2020
References
 1. International Diabetes Federation. IDF Diabetes Atlas - 2019. (2019). https ://doi.org/10.1289/image .ehp.v119.i03
 2. Deshpande, A. D., Harris-Hayes, M. & Schootman, M. Epidemiology of diabetes and diabetes-related complications. Phys. Ther. 
88, 1254–1264 (2008).
 3. Secrest, A.M., Washington, R.E. & Orchard, T.J. Chapter 35: Mortality in Type 1 Diabetes. in Diabetes in America 1–16 (2014).
 4. Bell, D. S. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26, 2433–2441 (2003).
 5. Beckman, J. A., Paneni, F., Cosentino, F. & Creager, M. A. Diabetes and vascular disease: pathophysiology, clinical consequences, 
and medical therapy: Part II. Eur. Heart J. 34, 2444–2456 (2013).
 6. Singh, G. M. et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled 
analysis. PLoS ONE 8, e65174 (2013).
 7. Boudina, S. Clinical manifestations of diabetic cardiomyopathy. Hear. Metab. 45, 10–14 (2009).
 8. Rubler, S. et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595–602 (1972).
 9. Schannwell, C. M., Schneppenheim, M., Perings, S., Plehn, G. & Strauer, B. E. Left ventricular diastolic dysfunction as an early 
manifestation of diabetic cardiomyopathy. Cardiology 98, 33–39 (2002).
 10. Shimizu, M. et al. Collagen remodelling in myocardia of patients with diabetes. J. Clin. Pathol. 46, 32–36 (1993).
 11. Hayat, S. A., Patel, B., Khattar, R. S. & Malik, R. A. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin. Sci. 107, 
539–557 (2004).
 12. Betz, B. & Conway, B. R. Recent advances in animal models of diabetic nephropathy. Nephron Exp. Nephrol. 126, 191–195 (2014).
 13. Rudberg, S. & Osterby, R. Decreasing glomerular filtration rate—an indicator of more advanced diabetic glomerulopathy in the 
early course of microalbuminuria in IDDM adolescents?. Nephrol. Dial. Transplant. 12, 1149–1154 (1997).
 14. Mauer, S. M., Lane, P., Zhu, D., Fioretto, P. & Steffes, M. W. Renal structure and function in insulin-dependent diabetes mellitus 
in man. J. Hypertens. Suppl. 10, 17–20 (1992).
 15. Breyer, M. D. et al. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 16, 27–45 (2005).
 16. AMDCC. Validation of Models of Cardiovascular Disease in Diabetes. 1–13 (2003).
 17. AMDCC. Validation of Mouse Models of Diabetic Nephropathy. 1–12 (2003).
 18. Nickerson, H. D. & Dutta, S. Diabetic complications: Current challenges and opportunities. J. Cardiovasc. Transl. Res. 5, 375–379 
(2012).
 19. Miric, G. et al. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. 
Pharmacol. 133, 687–694 (2001).
 20. Katoh, M. et al. Effects of imidapril and captopril on streptozotocin-induced diabetic nephropathy in mice. Eur. J. Pharmacol. 398, 
381–387 (2000).
 21. Fernandes, S. M. et al. The role of oxidative stress in streptozotocin-induced diabetic nephropathy in rats. Arch. Endocrinol. Metab. 
60, 443–449 (2016).
 22. Sembach, F. E. et al. Impact of sex on diabetic nephropathy and the renal transcriptome in UNx db/db C57BLKS mice. Physiol. 
Rep. 7, e14333 (2019).
 23. Arow, M. et al. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc. Diabetol. 
19, 7 (2020).
 24. Bolzán, A. D. & Bianchi, M. S. Genotoxicity of streptozotocin. Diabetes 512, 579–582 (2002).
 25. Camacho, P., Fan, H., Liu, Z. & He, J. Q. Small mammalian animal models of heart disease. Am. J. Cardiovasc. Dis. 6, 70–80 (2016).
 26. Bugger, H. & Abel, E. D. Rodent models of diabetic cardiomyopathy. Dis. Model. Mech. 2, 454–466 (2009).
 27. Eulálio, J. M. R. et al. Critical analysis and systematization of rat pancreatectomy terminology. Acta Cir. Bras. 31, 698–704 (2016).
 28. Tanigawa, K. et al. Effect of aging on B-cell function and replication in rat pancreas after 90% pancreatectomy. Pancreas 15, 53–59 
(1997).
 29. Hoit, B. D., Castro, C., Bultron, G., Knight, S. & Matlib, M. A. Noninvasive evaluation of cardiac dysfunction by echocardiography 
in streptozotocin-induced diabetic rats. J. Card. Fail. 5, 324–333 (1999).
 30. Grimm, D. et al. Development of heart failure following isoproterenol administration in the rat: role of the renin–angiotensin 
system. Cardiovasc. Res. 37, 91–100 (1998).
 31. Leenen, F. H., White, R. & Yuan, B. Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin–angiotensin 
system. Am. J. Physiol. Hear. Circ. Physiol. 281, 2410–2416 (2001).
 32. Zheng, S. et al. Uninephrectomy of diabetic OVE26 mice greatly accelerates albuminuria, fibrosis, inflammatory cell infiltration 
and changes in gene expression. Nephron Exp. Nephrol. 119, e21–e32 (2011).
 33. Uil, M. et al. Combining streptozotocin and unilateral nephrectomy is an effective method for inducing experimental diabetic 
nephropathy in the ‘resistant’ C57Bl/6J mouse strain OPEN. Sci. Rep. 8, 5542 (2018).
14
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:16130  | https://doi.org/10.1038/s41598-020-73046-8
www.nature.com/scientificreports/
 34. Goldstein, S. A. et al. Multimodality imaging of diseases of the thoracic aorta in adults: from the American society of echocardiog-
raphy and the European Association of cardiovascular imaging: endorsed by the society of cardiovascular computed tomography 
and society for cardiova. J. Am. Soc. Echocardiogr. 28, 119–182 (2015).
 35. Teichholz, L. E., Herman, V., Kreulen, T. & Gorlin, R. Problems in echocardiographic presence or absence volume determinations: 
correlations in the of asynergy. Am. J. Cardiol. 37, 7–11 (1976).
 36. Rieg, T. A High-throughput method for measurement of glomerular filtration rate in conscious mice. J. Vis. Exp. 75, 1–6 (2013).
 37. Paulsen, S. J., Vrang, N., Larsen, L. K., Larsen, P. J. & Jelsing, J. Stereological assessment of pancreatic beta-cell mass development 
in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function. J. Anat. 217, 624–630 (2010).
 38. Cullen-Mcewen, L. A., Armitage, J. A., Nyengaard, J. R. & Bertram, J. F. Estimating nephron number in the developing kidney 
using the physical disector/fractionator combination. Methods Mol. Biol. 886, 109–119 (2012).
 39. Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
 40. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome 
Biol. 15, 1–21 (2014).
 41. Liu, Y. Q., Nevin, P. W. & Leahy, J. L. β-Cell adaptation in 60% pancreatectomy rats that preserves normoinsulinemia and normo-
glycemia. Am. J. Physiol. Endocrinol. Metab. 279, 68–73 (2000).
 42. Jia, G., Demarco, V. G. & Sowers, J. R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy HHS Public Access. 
Nat. Rev. Endocrinol. 12, 144–153 (2016).
 43. Hotz, J., Oberna, R. G. & Clodi, P. H. Reserve capacity of the exocrine pancreas enzyme secretion and fecal fat assimilation in the 
95% pancrcatectomized rat. Gut 54, 1–28 (2005).
 44. Králová, E., Mokrán, T., Murín, J. & Stankovicová, T. Electrocardiography in two models of isoproterenol-induced left ventricular 
remodeling. Physiol. Res. 57, 83–89 (2008).
 45. Benjamin, I. J. et al. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ. Res. 65, 657–670 (1989).
 46. Golomb, E. et al. Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. Am. J. Physiol. 
Hear. Circ. Physiol. 267, 1496–1506 (1994).
 47. Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K. & Laakso, M. Mortality from coronary heart disease in subjects with type 2 
diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229–234 (1998).
 48. Fazel, R., Fang, J., Kline-Rogers, E. & Smith, D. E. Prognostic value of elevated biomarkers in diabetic and non-diabetic patients 
admitted for acute coronary syndromes. Heart 91, 388–390 (2005).
 49. Wu, H. et al. Epigenetic regulation of phosphodiesterases 2A and 3A underlies compromised β-adrenergic signaling in an iPSC 
model of dilated cardiomyopathy. Cell Stem Cell 17, 89–100 (2015).
 50. Roth, D. M. et al. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circ. J. 99, 
3099–3102 (1999).
 51. Tonneijck, L. et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J. Am. Soc. Nephrol. 
28, 1023–1039 (2017).
 52. Han, W. K., Bailly, V., Abichandani, R., Thadhani, R. & Bonventre, J. V. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for 
human renal proximal tubule injury. Kidney Int. 62, 237–244 (2002).
 53. Devarajan, P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand. J. Clin. Lab. Invest. 68, 
89–94 (2008).
 54. Carlsson, A. C. et al. Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and 
total mortality in type 2 diabetes Open Access. Cardiovasc. Diabetol. 15, 40 (2016).
 55. Hara, M. et al. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: Establishment of a highly 
sensitive ELISA to detect urinary podocalyxin. Diabetologia 55, 2913–2919 (2012).
 56. Vallon, V. et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents 
glomerular hyperfiltration in diabetic Akita mice. Am. J. Physiol. Ren. Physiol. 306, F194 (2014).
 57. Mima, A. et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes. Diabetes 
61, 2967–2979 (2012).
 58. Østergaard, M. V. et al. Automated image analyses of glomerular hypertrophy in a mouse model of diabetic nephropathy. Kidney360 
1, 469–479 (2020).
 59. Tikellis, C. et al. Characterization of renal angiotensin—converting enzyme 2 in diabetic nephropathy. Hypertension 41, 392–397 
(2003).
Acknowledgements
The authors would like to acknowledge the skilled assistance of Camilla Malec and Helene Dyhr who performed 
the pancreatectomy and uninephrectomy surgeries.
Author contributions
Conception and design of research: M.V.O., L.N.F., T.Sk., J.J., N.E.Z. Acquisition of data: L.T., M.V.O., A.A.P., 
P.J.P., R.T.L., T.Se., T.J.J., N.E.Z. Analysis and interpretation the data: L.T., M.V.O., P.J.P., A.J.M., L.N.F., T.X.P., 
T.Se., T.J.J., S.T.T., T.Sk., J.J., M.B.T., N.E.Z. Wrote the manuscript: L.T., M.V.O., J.J., N.E.Z. All authors read and 
approved the final manuscript.
Funding
The salary of L.T. is partly funded by Innovation Fund Denmark (Grant No. 7038-00070B). R.T.L. received a 
PhD studentship from the British Heart Foundation (Grant No. FS/14/59/31282).
Competing interests 
L.T., M.V.O., A.A.P., P.J.P., L.N.F., T.Se., S.T.T., J.J., N.E.Z. are employed by Gubra. The rest of the authors declare 
to have no competing interest.
Additional information
Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-73046 -8.
Correspondence and requests for materials should be addressed to N.E.Z.
Reprints and permissions information is available at www.nature.com/reprints.
15
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16130  | https://doi.org/10.1038/s41598-020-73046-8
www.nature.com/scientificreports/
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
